Objective: To investigate the association between blood lead level (BLL) and Alzheimer's disease (AD) mortality. Design: Prospective cohort study. Setting: US National Health and Nutrition Examination Survey (NHANES) 1988-94 and 1999-2008. Participants 21,308 subjects aged 40 years and over with a BLL ≥1.0 µg/dL. Main outcome measures: AD mortality from baseline until December 2019. Results: AD was the underlying cause of death for 350 participants. In the fully adjusted model with a calendar effect variable, log-transformed BLL was inversely associated with AD mortality among all subjects (HR: 0.57 [95% CI, 0.46, 0.70]). A similar finding was evident when BLL was modeled as a categorical variable, with hazard ratios of 0.69 (95% CI: 0.54, 0.88), 0.56 (0.39, 0.80), 0.36 (0.19, 0.70), and 0.31 (0.14, 0.72) for 2.5-4.9 µg/dL, 5.0-7.4 µg/dL, 7.5-9.9 µg/dL, and ≥10 µg/dL, when compared to 1-2.4 µg/dL (p-trend < 0.0001). Restricted cubic spline analysis confirmed an inverse dose-response relationship between BLL and AD mortality. Conclusions: Our study suggests an inverse association between lead exposure and AD mortality among US adults; however, the results should be interpreted with caution due to the observational nature of the study.